Applied Molecular Transport Announces Board Appointments
28 January 2022 - 08:30AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced the
appointment of John W. Smither to its Board of Directors and Chair
of its Audit Committee. AMT also announced that current Director,
Graham K. Cooper, has been named Executive Chair and current
Director, Helen S. Kim, has been named Lead Independent Director.
“We are delighted to have John join AMT’s Board
of Directors,” said Tahir Mahmood, Ph.D., chief executive officer
and co-founder of AMT. “John is a recognized industry leader whose
extensive financial and corporate strategy experience will be
instrumental as we anticipate four significant Phase 2 top-line
data readouts for oral AMT-101 this year, in addition to advancing
our transformative pipeline of novel biological therapeutics.”
Dr. Mahmood continued, “I am also pleased that
Graham will be assuming the role of Executive Chair and Helen will
be assuming the role of Lead Independent Director. Both Graham and
Helen have been invaluable AMT Board members and their tremendous
breadth and depth of experience in our space will continue to be
critical to the future growth of AMT. I look forward to working
alongside Graham as we scale AMT.”
Mr. Smither added, “I am delighted to join the
AMT Board of Directors during such a significant year for the
company. I look forward to contributing to AMT’s future success and
working with the other Board members, as AMT continues to execute
on the vision of delivering novel oral biologic product candidates
to treat autoimmune, inflammatory, metabolic, and other
diseases.”
Mr. Smither most recently served as chief
financial officer of Arcutis Biotherapeutics, Inc. Prior to
Arcutis, Mr. Smither was chief financial officer for Sienna
Biopharmaceuticals. Prior to joining Sienna Biopharmaceuticals, Mr.
Smither was interim chief financial officer for Kite Pharma during
its integration with Gilead, and prior to that, was chief financial
officer at Unity Biotechnology. Earlier, he served as chief
financial officer of Kythera Biopharmaceuticals, Inc. until it was
acquired by Allergan for $2.1 billion. Mr. Smither also served in
various roles at Amgen, including vice president of finance and
administration for Amgen’s European Division, head of internal
audit, and executive director of corporate accounting. Prior to
joining Amgen, he served as an audit partner at Ernst & Young
LLP, a public accounting firm. He also served on the Board of
Directors and Audit Committee Chairman of Achaogen, Inc., and
currently serves on the Board of Directors and Audit Committee
Chair of eFFECTOR Therapeutics.
Mr. Smither holds a Bachelor of Science in
Business Administration from California State University, Los
Angeles. Mr. Smither is a Certified Public Accountant (inactive)
and a member of the American Institute of Certified Public
Accountants, the California Society of Certified Public Accountants
and Financial Executives International.
About AMT-101AMT-101 is a novel
GI-selective, oral fusion of hIL-10 and AMT’s proprietary carrier
molecule, currently in development in four Phase 2 clinical trials
in inflammatory bowel diseases and rheumatoid arthritis. AMT-101 is
designed to cross the intestinal epithelial (IE) barrier with
limited entry into the bloodstream, thereby focusing hIL-10 at the
primary site of inflammation for UC and potentially avoiding the
side effects observed with systemic administration. By design,
AMT-101 is actively transported through the IE barrier into the GI
tissue, the primary site of inflammation in UC.
About Applied Molecular Transport
Inc.Applied Molecular Transport Inc. is a clinical-stage
biopharmaceutical company leveraging its proprietary technology
platform to design and develop a pipeline of novel oral biologic
product candidates to treat autoimmune, inflammatory, metabolic,
and other diseases. AMT’s proprietary technology platform allows it
to exploit existing natural cellular trafficking pathways to
facilitate the active transport of diverse therapeutic modalities
across the intestinal epithelial (IE) barrier. Active transport is
an efficient mechanism that uses the cell’s own machinery to
transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its
approach. AMT is developing additional oral biologic product
candidates in patient-friendly oral forms that are designed to
either target local intestinal tissue or enter systemic circulation
to precisely address the relevant pathophysiology of disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com
Forward-Looking StatementsThis
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such forward-looking
statements involve substantial risks and uncertainties. All
statements other than statements of historical facts contained in
this press release are forward-looking statements including
statements relating to AMT’s plans, expectations, forecasts and
future events. Such forward-looking statements include, but are not
limited to, the potential of, and expectations regarding AMT’s
technology platform and AMT’s internal manufacturing capabilities,
statements regarding the optimization or expansion of our product
development plans or the design of future clinical trials,
statements regarding the potential of AMT-101, AMT-126, AMT’s
respiratory carrier technology or regarding AMT-101 and AMT-126
clinical trials, including the timing of data readouts from such
trials and program updates, milestones for such trials, and our
ability to replicate past clinical development strategies,
statements regarding the potential for AMT’s product candidates to
treat or provide clinically meaningful outcomes for certain medical
conditions or diseases, and assumptions regarding the biological
mode of action of our product candidates and the potential to avoid
side effects with our product candidates. In some cases, you can
identify forward-looking statements by terminology such as
“believe,” “estimate,” “intend,” “may,” “plan,” “potentially,”
“will,” “expect,” “enable” or the negative of these terms or other
similar expressions. We have based these forward-looking statements
largely on our current expectations and projections about future
events and trends that we believe may affect our financial
condition, results of operations, business strategy and financial
needs. Actual events, trends or results could differ materially
from the plans, intentions and expectations disclosed in these
forward-looking statements based on various factors. Information
regarding the foregoing and additional risks may be found in the
section entitled “Risk Factors” in AMT’s Annual and Quarterly
Reports on Form 10-K and 10-Q filed with the Securities and
Exchange Commission (the “SEC”), and AMT’s future reports to be
filed with the SEC. These forward-looking statements are made as of
the date of this press release, and AMT assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law.
Investor Relations
Contact:Andrew ChangHead, Investor Relations &
Corporate Communicationsachang@appliedmt.com
Media Contacts:Alexandra
SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Mar 2023 to Mar 2024